Countries covered: United States
This updated 3rd edition of Marketdata's pioneering business analysis of this little researched $812 million market is a timely investigation, considering newly revised goals of the US Surgeon General for the "Healthy People 2010" program. Nearly 25% of American adults still smoke—the "hard core" segment. The smoking cessation market has been transformed, shifting from a retail emphasis to a more medical approach. OTC kits, devices, hypnosis seminars, etc. are in decline, while prescription nicotine gum, new drugs (Zyban), and 4 nicotine patches (previously by Rx but now all over-the-counter) are becoming more significant.
The study examines markets for: nicotine gum, patches, drugs, nasal sprays and inhalers, as well as profiles of all major commercial and non-profit organizations with cessation programs/services (Smoke Stopper, Smokenders, Smokeless, Addiction Mgmt. Systems, Amer. Lung Assn., Amer. Cancer Society, etc.). Market size from 1984-2004F. Also provides extensive smoker demographics, analysis of the role of Internet-based, MD, and pharmacist counseling, as well as a status report of corporate smoking restrictions and programs and the anti-smoking regulatory/social environment.
Related Reports:
Pharmaceuticals Industry Report
Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes
Prescription Drug Wholesaling in the US - Industry Risk Rating Report
Antidepressants Market Forecast
The US Government's Financial Support to Push Comparative Effectiveness Research
Snapshots Australia Pharmaceuticals 2009
Snapshots Bulgaria Pharmaceuticals 2009
Snapshots France Pharmaceuticals 2009
Global Pharmaceuticals Industry Report
|
(0 items)
